Publications

Just How Good an Investment Is the Biopharmaceutical Sector?

2017
Thakor, Richard T., Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, and Andrew W. Lo (2017), Just How Good an Investment Is the Biopharmaceutical Sector?, Nature Biotechnology 35 (12), 1149–1157.

Re-Inventing Drug Development: A Case Study of the I-SPY 2 Breast Cancer Clinical Trials Program

2017
Das, Sonya, and Andrew W. Lo (2017), Re-Inventing Drug Development: A Case Study of the I-SPY 2 Breast Cancer Clinical Trials Program, Contemporary Clinical Trials 62, 168–174.

Accelerating Biomedical Innovation: A Case Study of the SPARK Program at Stanford University, School of Medicine

2017
Kim, Esther S., Paige M. C. Omura, and Andrew W. Lo (2017), Accelerating Biomedical Innovation: A Case Study of the SPARK Program at Stanford University, School of Medicine, Drug Discovery Today 22 (7), 1064–1068.

Discussion: New Directions for the FDA in the 21st Century

2017
Lo, Andrew W. (2017), Discussion: New Directions for the FDA in the 21st Century, Biostatistics 18 (3), 404–407.

P-Values vs. Patient Values: A New Statistical Approach to the Drug-Approval Quandary

2016
Lo, Andrew W. (2016), P-Values vs. Patient Values: A New Statistical Approach to the Drug-Approval Quandary, Milken Institute Review, Second Quarter, 56–63.

Letter to Senators Wyden and Grassley: Comment on Their Sovaldi Report

2016
Lo, Andrew W. (2016), Letter to Senators Wyden and Grassley: Comment on Their Sovaldi Report, February 27.

Health, Wealth, and the 21st Century Cures Act

2016
Lo, Andrew W., Tomas J. Philipson, and Andrew C. von Eschenbach (2016), Health, Wealth, and the 21st Century Cures Act, JAMA Oncology 2 (1), 17–18.

Price, Value, and the Cost of Cancer Drugs

2016
Fojo, Tito, and Andrew W. Lo (2016), Price, Value, and the Cost of Cancer Drugs, The Lancet Oncology 17 (1), 3–5.
   

Business Models to Cure Rare Disease: A Case Study of Solid Biosciences

2016
Kim, Esther S., and Andrew W. Lo (2016), Business Models to Cure Rare Disease: A Case Study of Solid Biosciences, Journal of Investment Management 14 (4), 87–101.

Health Care Loans For Hep C Cure

2016
Lo, Andrew W., and David Weinstock (2016), ‘Health Care Loans’ for Hep C Cure, Boston Globe, February 24.

Buying Cures Versus Renting Health: Financing Health Care with Consumer Loans

2016
Montazerhodjat, Vahid, David M. Weinstock, and Andrew W. Lo (2016), Buying Cures versus Renting Health: Financing Health Care with Consumer Loans, Science Translational Medicine 8 (327), 327ps6.

Financing Drug Discovery via Dynamic Leverage

2016
Montazerhodjat, Vahid, John J. Frishkopf, and Andrew W. Lo (2016), Financing Drug Discovery via Dynamic Leverage, Drug Discovery Today 21 (3), 410–414.

Lessons From Hollywood: A New Approach To Funding R&D

2016
Lo, Andrew W., and Gary Pisano (2016), Lessons From Hollywood: A New Approach to Funding R&D, Sloan Management Review 57 (2), 47–57.

Megafunding Drug Research

2015
Jung, Edward, and Andrew W. Lo (2015), Megafunding Drug Research, Project Syndicate, December 9.

Funding Translational Medicine via Public Markets: The Business Development Company

2015
Forman, Sandra M., Andrew W. Lo, Monica Shilling, and Grace K. Sweeney (2015), Funding Translational Medicine via Public Markets: The Business Development Company, Journal of Investment Management 13 (4), 9–32.